Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma


A Randomized Phase III Trial of Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon A-2B Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients With Metastatic Malignant Melanoma


Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person`s white blood cells to kill melanoma cells. Interferon alfa may interfere with the growth of tumor cells. It is not yet known whether combination chemotherapy plus interleukin-2 and interferon alfa is more effective than combination chemotherapy alone for metastatic melanoma.


Randomized phase III trial to compare combination chemotherapy with or without interleukin-2 and interferon alfa in treating patients who have metastatic melanoma that cannot be treated by surgery.

Study Status: Completed


Condition Intervention Phase
Melanoma (Skin) Biological: aldesleukin
Biological: filgrastim
Biological: recombinant interferon alfa
Drug: cisplatin
Drug: dacarbazine
Drug: vinblastine
Phase 3

Verified by Eastern Cooperative Oncology Group January, 2010

Sponsored by: Eastern Cooperative Oncology Group
Information provided by: Eastern Cooperative Oncology Group identifier: NCT00003027

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Active Control, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Michael B. Atkins, MD., Study Chair
Lawrence E. Flaherty, MD., Study Chair
David M. Gustin, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site